DrugPatentWatch Database Preview
SOOLANTRA Drug Profile
» See Plans and Pricing
When do Soolantra patents expire, and when can generic versions of Soolantra launch?
Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has seventy-five patent family members in twenty-eight countries.
The generic ingredient in SOOLANTRA is ivermectin. There are five drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the ivermectin profile page.
US ANDA Litigation and Generic Entry Outlook for Soolantra
A generic version of SOOLANTRA was approved as ivermectin by EDENBRIDGE PHARMS on October 24th, 2014.
Summary for SOOLANTRA
International Patents: | 75 |
US Patents: | 11 |
Applicants: | 1 |
NDAs: | 1 |
Suppliers / Packagers: | 2 |
Bulk Api Vendors: | 64 |
Clinical Trials: | 6 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for SOOLANTRA |
Drug Sales Revenues: | Drug sales revenues for SOOLANTRA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SOOLANTRA |
What excipients (inactive ingredients) are in SOOLANTRA? | SOOLANTRA excipients list |
DailyMed Link: | SOOLANTRA at DailyMed |



Recent Clinical Trials for SOOLANTRA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
Zydus Worldwide DMCC | Phase 3 |
Catawba Research, LLC | Phase 3 |
Pharmacology for SOOLANTRA
Drug Class | Antiparasitic Pediculicide |
Paragraph IV (Patent) Challenges for SOOLANTRA
Tradename | Dosage | Ingredient | NDA | Submissiondate |
---|---|---|---|---|
SOOLANTRA | CREAM;TOPICAL | ivermectin | 206255 | 2016-12-30 |
US Patents and Regulatory Information for SOOLANTRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SOOLANTRA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | Start Trial | Start Trial |
Galderma Labs Lp | SOOLANTRA | ivermectin | CREAM;TOPICAL | 206255-001 | Dec 19, 2014 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SOOLANTRA
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 243315 | Start Trial |
China | 105828825 | Start Trial |
South Korea | 101863085 | Start Trial |
Austria | 516037 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for SOOLANTRA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1620113 | C 2015 036 | Romania | Start Trial | PRODUCT NAME: IVERMECTINA; NATIONAL AUTHORISATION NUMBER: RO7674/2015/01, RO7674/2015/02, RO7674/2015/03, RO7674/2015/04, RO7674/2015/05; DATE OF NATIONAL AUTHORISATION: 20150526; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): MALTA MA117/01101; DATE OF FIRST AUTHORISATION IN EEA: 20150402 |
1620113 | 2015/046 | Ireland | Start Trial | PRODUCT NAME: IVERMECTIN; NAT REGISTRATION NO/DATE: PA0590/028/001 20150424; FIRST REGISTRATION NO/DATE: MA117/01101 20150402 |
1620113 | PA2015033,C1620113 | Lithuania | Start Trial | PRODUCT NAME: IVERMEKTINAS; NAT. REGISTRATION NO/DATE: LT/1/15/3726/001 - LT/1/15/3726/005 20150513; FIRST REGISTRATION: MA117/01101 20150402 |
1620113 | C01620113/01 | Switzerland | Start Trial | PRODUCT NAME: IVERMECTINUM; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 65561 20.12.2016 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |